Inhalon
Winnie H Wan is currently the Director at Inhalon. Prior to this, they were with Life Science Angels, Santa Clara University, and Nanotech Biomachines, Inc., where they served as Board Director and Advisor. From December 2009 to December 2016, they were the Exec. Chairman & CEO of OncoHealth Corp., a start-up that commercialized novel proprietary diagnostics for HPV- associated cancers. Prior to this, they were with Chameleon Biosciences, Inc., Kryptos Biotechnologies, Inc., and Inhalon Biopharma, Inc. Winnie is also the founder and former CEO of BEING BioPharma, which they ran from January 2008 to December 2010.
Winnie H Wan has a PhD in Biochemistry from Yale University, a BA in Chemistry from Skidmore College, and an MBA in Business Management from Columbia Business School.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Inhalon
Inhalon Biopharma is developing an inhaled immunotherapy platform for treating acute respiratory infections (ARI), such as syncytial virus (RSV), influenza, metapneumovirus (MPV), parainfluenza virus (PIV), adenovirus, severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS). Today there are no approved treatments for a wide range of ARIs that can lead to hospitalization, long-term health complications, and sometimes death.